title: The effect of drug treatment on neurogenesis in Parkinson's disease.
abstract: There has been recent interest in the possibility that impaired neurogenesis may contribute to the decline in neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease (PD). We have investigated the effects of commonly used treatments for PD on neural stem cell (NSC) activity in nondemented patients. Postmortem of brain tissue containing the subventricular zone (SVZ) and ependymal layer cells was obtained from 32 nondemented patients with PD. NSC activity was assessed by immunohistochemical staining for RNA-binding protein Musashi1. Regression analyses were then used to identify which clinical factors independently influenced NSC activity. Disease duration was negatively associated with SVZ Musashi1 staining, whereas lifetime levodopa was positively associated in this region. Our findings suggest a positive impact of chronic L-dopa use on the number of NSC in the SVZ of PD patients, which may have relevance for future studies on neuroprotection in neurodegenerative diseases.
authors.affiliation: Reta Lila Weston Institute of Neurological Studies, University College London, London, United Kingdom. sosulliv@ion.ucl.ac.uk
authors.forename: Sean S
authors.initials: SS
authors.lastname: O'Sullivan
authors.forename: Mary
authors.initials: M
authors.lastname: Johnson
authors.forename: David R
authors.initials: DR
authors.lastname: Williams
authors.forename: Tamas
authors.initials: T
authors.lastname: Revesz
authors.forename: Janice L
authors.initials: JL
authors.lastname: Holton
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Lees
authors.forename: Elaine K
authors.initials: EK
authors.lastname: Perry
mesh_terms: D000368:Aged; D000978:Antiparkinson Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002454:Cell Differentiation / Q000187:drug effects; D002552:Cerebral Ventricles / Q000473:pathology*; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D007980:Levodopa / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009419:Nerve Tissue Proteins / Q000378:metabolism; D058953:Neural Stem Cells / Q000187:drug effects; D055495:Neurogenesis / Q000187:drug effects* / Q000502:physiology; D010300:Parkinson Disease / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D011180:Postmortem Changes; D016601:RNA-Binding Proteins / Q000378:metabolism; D012044:Regression Analysis; D012189:Retrospective Studies
chemical_list: D000978:Antiparkinson Agents; C491297:MSI1 protein, human; D009419:Nerve Tissue Proteins; D016601:RNA-Binding Proteins; D007980:Levodopa